These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18987906)

  • 1. Biostatistical aspects for the use of evidence based medicine in health technology assessment.
    Freemantle N
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():31-43. PubMed ID: 18987906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
    Müller T
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
    [No Abstract]   [Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies.
    Falissard B; Izard V; Xerri B; Bouvenot G; Meyer F; Degos L
    Int J Technol Assess Health Care; 2010 Jan; 26(1):124-30. PubMed ID: 20059790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From evidence assessments to coverage decisions?: the case example of glinides in Germany.
    Kreis J; Busse R
    Health Policy; 2012 Jan; 104(1):27-31. PubMed ID: 22136812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Public financing for off-label use of drugs].
    Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
    Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delisting policy reform in South Korea: failed or policy change?
    Lee H; Kim J
    Value Health; 2012 Jan; 15(1):204-12. PubMed ID: 22264990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
    Maclure M; Carleton B; Schneeweiss S
    Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug policy: the challenge is to overcome fragmentation.
    McFarlance A
    Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to an evidence-based approach to interventional techniques in the management of chronic spinal pain.
    Manchikanti L; Singh V; Helm S; Schultz DM; Datta S; Hirsch JA;
    Pain Physician; 2009; 12(4):E1-33. PubMed ID: 19668280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland.
    Bending M; Hutton J; McGrath C
    Int J Technol Assess Health Care; 2012 Apr; 28(2):187-94. PubMed ID: 22559763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Statin therapy: cost-effectiveness and evaluation of evidence as criterium for improving expenditure within the National Health Program].
    Magi L; Sforza P; Rafaiani S; Settembri P; Morosini P
    Recenti Prog Med; 2006 May; 97(5):257-61. PubMed ID: 16838556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Common Drug Review: a NICE start for Canada?
    McMahon M; Morgan S; Mitton C
    Health Policy; 2006 Aug; 77(3):339-51. PubMed ID: 16214257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.